In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Juno buys Stage Cell Therapeutics for €52mm plus €135mm in earn-outs

Executive Summary

Juno Therapeutics Inc. paid €52mm ($59mm) in cash and issued 486k of its shares (valued at €20mm) to acquire the 95% of German biotech Stage Cell Therapeutics GMBH that it didn’t already down. Stage Cell will operate as a wholly owned subsidiary, and will be renamed Juno Therapeutics GMBH.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Partial Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies